natgillin/translations-raw huggingface dataset:
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including telavancin (see section 4.8), and may range in severity from mild to life-threatening.
O kolitisu, povezanem z antibiotiki, in psevdomembranskem kolitisu so poročali pri skoraj vseh antibakterijskih sredstvih, vključno s telavancinom (glejte poglavje 4.8), ki lahko sega od blagega do takšnega, ki ogroža življenje.
Obese patients (defined as those with BMI > 30 kg/m2) should receive telavancin at the reduced dose of 7.5 mg/kg once every 24 hours (see section 5.2).
Debeli bolniki (opredeljeni kot tisti z ITM > 30 kg/m2) prejmejo telavancin v zmanjšanem odmerku 7,5 mg/kg enkrat na 24 ur (glejte poglavje 5.2).
A clinical QTc study with telavancin doses of 7.5 and 15 mg/kg versus vehicle and an active comparator (400 mg moxifloxacin) showed that once daily dosing for 3 days resulted in a mean vehicle corrected increase in QTcF by 4.1 and 4.5 millisecond, respectively, compared to a 9.2 millisecond increase observed with the comparator.
Klinična študija QTc z odmerkoma telavancina 7,5 in 15 mg/kg v primerjavi z vehiklom in aktivnem komparatorju (400 mg moksifloksacina) je pokazala, da je en dnevni odmerek za 3 dni povzročil srednje povišanje QTcF s popravkom medija za 4,1 in 4,5 milisekund v primerjavi z 9,2 milisekundnim povišanjem, ki je bilo opaženo pri komparatorju.
Telavancin may interfere with some laboratory tests that measure proteins in the urine.
Telavancin lahko ovira nekatere laboratorijske teste, ki merijo beljakovine v urinu.
Also patients with baseline QTc >500 msec, congenital long QT syndrome, uncompensated heart failure, or abnormal K+ or Mg2+ blood levels that could not be corrected, severely neutropenic (absolute neutrophil count <500/mm3) or anticipated to develop severe neutropenia due to prior or planned chemotherapy, or who had HIV with CD4 count <100/mm3 during the last 6 months were excluded.
Izključeni so bili tudi bolniki s QTc z izhodiščem >500 ms, kongenitalnim sindromom dolgega QT, nekompenzirano odpovedjo srca ali neobičajnimi vrednostmi K+ ali Mg2+ v krvi, ki jih ni bilo mogoče popraviti, hudo nevtropenijo (absolutno število nevtrofilcev <500/mm³) ali pri katerih se pričakuje, da bodo razvili hudo nevtropenijo zaradi predhodne ali načrtovane kemoterapije in tisti, ki so imeli HIV s številom CD4 <100/mm³ v zadnjih
The pharmacokinetics of telavancin have not been evaluated in severe hepatic impairment (Child-Pugh class C).
Farmakokinetika telavancina ni bila ocenjena pri hujši jetrni okvari (Child-Pugh razred C).
Telavancin interferes with urine qualitative dipstick protein assays, as well as quantitative dye methods (e.g. pyrogallol red molybdate).
Telavancin ovira kvalitativno analizo proteinov s testnimi lističi za urin in kvantitavnimi metodami obarvanja (npr. pirogalol rdeč molibdat).
Rapid intravenous infusions of antimicrobial agents of the class of glycopeptides have been associated with red man syndrome-like reactions, including flushing of the upper body, urticaria, pruritus or rash (see section 4.8).
Hitre intravenske infuzije protimikrobnih sredstev iz razreda glikopeptidov so bile povezane z reakcijami podobnimi eritrodermu , vključno z rdečico na zgornjem delu telesa, urtikarijo, pruritusom ali izpuščaji (glejte poglavje 4.8).
In the pooled clinical studies (NP and complicated skin and soft tissue infection (cSSTI)), renal adverse reactions were reported more frequently in patients receiving telavancin compared with vancomycin (3.8% vs. 2.2%, respectively).
V združenih kliničnih študijah (bolnišnična pljučnica in zapletene okužbe kože in mehkega tkiva (cSSTI)) so pogosteje poročali o neželenih učinkih na ledvicah pri bolnikih, ki so prejemali telavancin, kot pri bolnikih, ki so prejemali vankomicin (3,8 % proti 2,2 %).
Pharmacokinetic parameters (mean (SD)) following a single dose administration of 7.5 mg/kg telavancin in volunteers with varying degrees of renal function are provided below.
Farmakokinetični parametri (povprečni (SD)) po enkratnem danem odmerku 7,5 mg/kg telavancina pri prostovoljcih z variirajočimi stopnjami ledvične funkcije so navedeni spodaj.
• That there is an identified risk of ototoxicity and patients developing ototoxicity signs or symptoms or patients receiving other medicinal products with ototoxic potential should be
• Obstaja ugotovljeno tveganje za ototoksičnost ter da je treba bolnike, pri katerih se razvijejo znaki ali simptomi ototoksičnosti, oz. bolnike, ki prejemajo druga zdravila z ototoksičnim potencialom, skrbno oceniti in spremljati.
The other ingredients are hydroxypropylbetadex, mannitol (E421), sodium hydroxide (E524) (for pH adjustment) and hydrochloric acid (E507) (for pH adjustment).
Druge sestavine so hidroksipropilbetadeks, manitol (E421), natrijev hidroksid (E524) (za uravnavanje pH) in klorovodikova kislina (E507) (za uravnavanje pH).
Following administration of a single 10 mg/kg dose of telavancin, the pharmacokinetics of telavancin in subjects with moderate hepatic impairment (Child-Pugh class B) were similar to that observed in subjects with normal hepatic function.
Pri dajanju enojnega 10 mg/kg odmerka telavancina, je bila farmakokinetika telavancina pri osebah z zmerno jetrno okvaro (Child-Pugh razred B) podobna tisti, ugotovljeni pri osebah z običajno jetrno funkcijo.
A retrospective, chart review, post authorisation safety study (PASS) shall be conducted with the objective to further characterise the adverse drug reaction profile of telavancin when used in the clinical setting.
Izvedena bo naknadna študija o varnosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PASS) z namenom nadaljnje opredelitve profila o neželenih učinkih zdravila telavancin ob uporabi v kliničnem okolju.
Patients with renal impairment should receive an initial dose according to calculated or measured creatinine clearance as presented in the table below.
Bolniki z ledvično okvaro prejmejo začetni odmerek glede na ocenjen ali izmerjen očistek kreatinina, kot je opisano v spodnji preglednici.
The clearance of telavancin by continuous venovenous haemofiltration (CVVH) was evaluated in an in vitro study.
Očistek telavancina s kontinuirano venovensko hemofiltracijo (CVVH) je bil ocenjen z in vitro študijo.
If you also have other bacteria that cause your infection, your doctor may prescribe other antibiotics in
Če vašo okužbo povzročajo tudi druge bakterije, vam lahko zdravnik poleg zdravila VIBATIV
• That there is a risk of infusion related reactions including red man syndrome-like reactions.
• Obstaja tveganje za reakcije, povezane z infundiranjem, vključno z reakcijami, ki so podobne
Very common: may affect more than 1 in 10 people
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
Initial dose and dosage adjustments during treatment should be made based on calculated or measured creatinine clearance according to the dosing regimen in section 4.2.
Začetni odmerek in prilagoditve odmerka med zdravljenjem je potrebno določiti glede na ocenjeni ali izmerjeni očistek kreatinina v skladu z režimom odmerjanja v poglavju 4.2.
In mixed infections where Gram-negative and/or certain types of anaerobic bacteria are suspected, VIBATIV should be co-administered with appropriate antibacterial agent(s).
Pri mešanih okužbah, kjer obstaja sum na gramnegativne in/ali določene vrste anaerobnih bakterij, je treba poleg zdravila VIBATIV dajati tudi druga primerna antibakterijska
Telavancin may interfere with some laboratory tests that measure how well your blood is clotting.
Telavancin lahko ovira nekatere laboratorijske teste, ki merijo strjevanje vaše krvi.
During treatment dose adjustments according to the table should be made based on calculated or measured creatinine clearance in patients with clinically relevant changes in renal function.
Med zdravljenjem je potrebno prilagajati odmerek glede na preglednico, ki temelji na ocenjenem ali izmerjenem očistku kreatinina pri bolnikih s klinično pomembnimi spremembami ledvične funkcije.
As with other glycopeptides, ototoxicity (deafness and tinnitus) has been reported in patients treated with telavancin (see section 4.8).
Kot pri ostalih glikopeptidih so tudi tukaj poročali o ototoksičnosti (gluhost in tinitus), pri bolnikih, ki so bili zdravljeni s telavancinom (glejte poglavje 4.8).
The nosocomial pneumonia (NP) studies excluded known or suspected pulmonary disease like granulomatous diseases, lung cancer, or other malignancy metastatic to the lungs; cystic fibrosis or active tuberculosis; Legionella pneumophila pneumonia; meningitis, endocarditis, or osteomyelitis; refractory shock defined as supine systolic blood pressure <90 mm Hg for >2 hours with evidence of hypoperfusion or requirement for high-dose sympathomimetic agents.
Iz študij bolnišnične pljučnice so bile izključene znane pljučne bolezni in sumi nanje, kot so granulomatozne bolezni, pljučni rak ali druge maligne metastaze pljuč; cistična fibroza ali aktivna tuberkoloza, pljučnica Legionella pneumophila; meningitis, endokarditis ali osteomielitis; refraktorni šok, opredeljen kot počasen sistolični krvni pritisk <90 mm Hg za >2 uri z dokazano hipoperfuzijo ali potrebo po visokemu odmerku simpatomimetikov.
VIBATIV must be reconstituted and then further diluted prior to administration by intravenous infusion through a dedicated line or through a Y-site over a 60 minute period.
Pred intravenskim infundiranjem je potrebno zdravilo VIBATIV rekonstituirati in nato nadalje razredčiti; infundiranje poteka po posebni cevki ali skozi Y-podaljšek v obdobju 60 minut.
Telavancin has no effect on platelet aggregation.
Telavancin ne vpliva na agregacijo trombocitov.
Reconstituted concentrate must be further diluted prior to administration.
Rekonstituirani koncentrat je potrebno nadalje razredčiti pred uporabo.
Your doctor will tell you if this is the case and may decide to monitor you more closely during treatment.
Vaš zdravnik vas bo o tem obvestil in se lahko odloči, da vas bo med zdravljenjem podrobneje opazoval.
In studies on fertility in male rats, decreases in sperm motility and epididymal sperm counts as well as an increase in the frequency of abnormal sperm were demonstrated after 10 weeks of intravenous administration of telavancin.
Pri študijah fertilnosti samcev podgan, se je po 10 tednih intravenskega odmerjanja telavancina pojavilo povečanje gibanja spermijev in števila spermijev v obmodku kakor tudi povečanje v pogostosti abnormalnih spermijev.
The mean (SD) maximum telavancin concentration (Cmax) amounts to 108 (26) µg/ml at steady state at a once daily dose of 10 mg/kg infused over a period of 1 h (tmax) and then falls to a trough value of 8.55 (2.84) µg/ml (C24h ).
Povprečna (SD) najvišja koncentracija telavancina (Cmax) znaša 108 (26) µg/ml v stanju dinamičnega ravnovesja pri dnevnem odmerku 10 mg/kg infundiranem v času 1 ure (tmax), nato pa pada do najnižje vrednosti 8,55 (2,84) µg/ml (C24h).
In the clinical studies, patients with pre existing acute renal failure receiving telavancin had an increased risk of mortality.
V kliničnih študijah so imeli bolniki s predhodno akutno odpovedjo ledvic, ki so prejemali telavancin, povečano tveganje smrtnosti.
• There is a risk of QTc prolongation and Vibativ should be used with caution in patients taking medicinal products known to prolong the QT interval.
• Obstaja tveganje za podaljšanje intervala QTc, zato je treba zdravilo Vibativ uporabljati previdno pri bolnikih, ki jemljejo zdravila, za katera je znano, da podaljšujejo interval QTc.
Ex vivo platelet aggregation Chromogenic factor Xa assay Functional (chromogenic) factor X assay Bleeding time
Analiza funkcionalnega (kromogenega) faktorja X Čas krvavenja
In rats and dogs vacuolisation of the epididymal tubular epithelium cells was also noted, and this finding did not show reversibility after a recovery period of 4 weeks.
Pri podganah in psih pa je bila prav tako opazna vakuolizacija celic tubularnega epitelija obmodka, ki pa ni bila odpravljiva po 4-tedenskem okrevanju.
The solution should only be used if the solution is clear and free from particles.
Raztopina se lahko uporabi le, če je bistra in ne vsebuje delcev.
The MAH shall agree the communication plan for the DHPC letter with the National Competent Authority in the Member States where the letter will be
Imetnik dovoljenja za promet z zdravilom se o načinu posredovanja obvestila DHPC dogovori s pristojnim nacionalnim organom v državah članicah, v katerih bo obvestilo razdeljeno.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with telavancin should be made taking into account the benefit of breastfeeding to the child and the benefit of telavancin therapy to the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja s telavancinom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti
Pharmacotherapeutic group: Antibacterials for systemic use, glycopeptide antibacterials, ATC code:
Farmakoterapevtska skupina: Druge protimikrobne učinkovine, glikopeptidni antibiotiki, oznaka ATC:
VIBATIV is used to treat adult patients with infections of the lungs that have developed in the hospital, including patients on artificial ventilation, when these infections are known or suspected to be caused by bacteria called methicillin-resistant Staphylococcus aureus (MRSA).
Zdravilo VIBATIV se uporablja za zdravljenje odraslih bolnikov z okužbami pljuč, ki so se razvile v bolnišnici, vključno z bolniki na umetnem predihavanju, kadar je znano oz. kadar sumimo, da njihovo okužbo povzroča na meticilin odporna bakterija Staphylococcus aureus (MRSA).
Following administration of a single dose of telavancin 7.5 mg/kg to subjects with end-stage renal disease, approximately 5.9% of the administered dose of telavancin was recovered in the dialysate following 4 hours of haemodialysis.
Po dajanju enega odmerka telavancina 7,5 mg/kg bolnikom z ledvično boleznijo v zadnjem stadiju je bilo v dializatu približno 5,9 % danega odmerka telavancina v 4 urah po hemodializi.
No adjustment of dosage is required for patients with mild to moderate degrees of hepatic impairment (see section 4.2).
Za bolnike z blagimi do zmernimi stopnjami jetrne okvare prilagoditev odmerka ni potrebna (glejte poglavje 4.2).
The use in patients with acute renal failure or creatinine clearance (CrCl) <30 ml/min including patients undergoing haemodialysis is contraindicated (see section 4.3).
Uporaba pri bolnikih z akutno ledvično odpovedjo ali z očistkom kreatinina (CrCl) <30 ml/min, vključno z bolniki na hemodializi je kontraindicirana (glejte poglavje 4.3).
An increase in the number of stillborn pups was observed in these pre- and post-natal studies (see section 4.3).
V teh prenatalnih in postnatalnih študijah je bilo ugotovljeno povečanje števila mrtvorojenih mladičev (glejte poglavje 4.3).
Type I clear glass vials with rubber stoppers and aluminium/plastic flip off cap.
Viale iz prozornega stekla tipa I z gumijastimi zamaški in aluminijasto/plastično zaporko.
Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with a creatinine clearance of 30-50 ml/min (see section 4.2).
Ker je izločanje preko ledvic primarna pot izločanja, je potrebna prilagoditev odmerka pri bolnikih z očistkom kreatinina od 30-50 ml/min (glejte poglavje 4.2).
Preparation of final diluted solution for infusion
Priprava končne razredčene raztopine za infuzijo
After 13 weeks of treatment, reversible seminiferous tubular degeneration was observed in the testis of rats.
Po 13 tednih zdravljenja, so v modih podgan ugotovili reverzibilno seminiferno tubularno degeneracijo.
Do not use VIBATIV after the expiry date that is stated on the label and carton after EXP: The expiry date refers to the last day of that month.
Zdravila VIBATIV ne smete uporabljati po datumu izteka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP:.
Your doctor may monitor your hearing during treatment.
Vaš zdravnik se lahko odloči, da bo med zdravljenjem spremljal vaš sluh.
The apparent distribution volume of telavancin at steady-state in healthy adult subjects was
Navidezen volumen porazdelitve telavancina v stanju dinamičnega ravnovesja pri zdravih odraslih
Rare: may affect up to 1 in 1,000 people deafness
Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov)
There is no known cross-resistance between telavancin and other non-glycopeptide classes of antibiotics.
Ni znane navzkrižne odpornosti med telavancinom in drugimi neglikopeptidnimi razredi
There is no human experience with telavancin.
V zvezi s telavancinom ni nobenih izkušenj pri ljudeh.
It is unknown whether telavancin is excreted in human breast milk.
Ni znano, ali se telavancin izloča v materino mleko.
Reconstitution time is not more than 5 minutes for the vial containing 250 mg.
Rekonstitucija traja največ 5 minut za vialo z 250 mg vsebino.
No clinically significant gender-related differences in telavancin pharmacokinetics have been observed.
V farmakokinetiki telavancina ni bilo opaženih nobenih klinično pomembnih razlik, povezanih s spolom.
Shelf life of powder as packaged for sale: 4 years Shelf life of reconstituted concentrate: The reconstituted concentrate should be diluted immediately
Rok uporabnosti praška v viali: 4 leta Rok uporabnosti rekonstituiranega koncentrata: Rekonstituiran koncentrat je potrebno razredčiti takoj
The telavancin medicinal product, which contains the excipient hydroxypropylbetadex (HP-β-CD), induced adverse effects in animal studies at plasma concentrations that were in the same range as clinical exposure levels and with possible relevance to clinical use.
Zdravilo telavancin, ki vsebuje pomožno snov hidroksipropilbetadeks (HP-β-CD), je sprožilo neželene učinke v študijah na živalih v plazemskih koncentracijah, ki so enake terapevtskim, zato
Caution is warranted when using telavancin to treat patients taking medicinal products known to prolong the QT interval.
Previdnost je potrebna pri uporabi telavancina pri bolnikih, ki jemljejo zdravila, za katera je znano, da podaljšujejo interval QT.
VIBATIV powder for concentrate for solution for infusion is provided as a 30 ml or 50 ml clear glass vial with rubber stopper, with an aluminium closure with plastic flip-off caps.
Prašek za koncentrat za raztopino za infundiranje VIBATIV je pakiran v 30 ml ali 50 ml vialo iz prozornega stekla z gumijastim zamaškom z aluminijasto zaporko in plastično zaporko.
Telavancin exerts concentration-dependent bactericidal activity against susceptible Gram-positive bacteria.
Telavancin kaže baktericidno dejavnost proti občutljivim grampozitivnim bakterijam, odvisno od koncentracije.
Telavancin dose (mg) = 10 mg/kg (or 7.5 mg/kg) x patient body weight (in kg) Volume of reconstituted concentrate (ml) = Telavancin dose (mg)/15 (mg/ml)
Odmerek telavancina (mg) = 10 mg/kg (ali 7,5 mg/kg) x masa bolnika (v kg) Volumen rekonstituiranega koncentrata (ml) = odmerek telavancina (mg)/15 (mg/ml)
Shelf life of diluted product: Chemical and physical in use stability of the reconstituted solution and the diluted solution in the infusion bag has been demonstrated for 24 hours under refrigeration (2-8°C).
Rok uporabnosti razredčene raztopine : Kemijska in fizikalna obstojnost rekonstituirane raztopine in razredčene raztopine v infuzijski vrečki je bila dokazana za obdobje 24 ur v hladilniku (2-8°C).
The MAH shall ensure that at the launch of Vibativ, all physicians who are expected to prescribe or use Vibativ are provided with a Direct Healthcare Professional Communication letter, the text of which is appended to the CHMP assessment report.
Imetnik dovoljenja za promet z zdravilom mora poskrbeti, da bodo ob začetku trženja zdravila Vibativ vsi zdravniki, za katere se pričakuje, da bodo predpisovali ali uporabljali zdravilo Vibativ, imeli na voljo Neposredno obvestilo za zdravstvene delavce (DHPC), ki je priloženo poročilu Odbora za zdravila za uporabo v humani medicini (CHMP) o oceni zdravila.
If these symptoms occur you must inform your doctor or nurse immediately.
Če se ti simptomi pojavijo, takoj obvestite svojega
Caution should be exercised when prescribing telavancin to patients with a prior history of hypersensitivity reaction to vancomycin.
Pri predpisovanju telavancina bolnikom, ki so v preteklosti imeli preobčutljivostno reakcijo na vankomicin, je potrebna previdnost.
Each vial contains 250 mg or 750 mg telavancin (as hydrochloride).
Ena viala vsebuje 250 mg ali 750 mg telavancina (v obliki klorida).
In addition, caution is warranted when using telavancin to treat patients with congenital long QT syndrome, known prolongation of the QTc interval, uncompensated heart failure,
Poleg tega je previdnost potrebna pri uporabi telavancina za zdravljenje bolnikov s kongenitalnim sindromom dolgega intervala QT, znanim podaljšanjem intervala QTc, nekompenzirano odpovedjo srca ali hudo hipertrofijo levega prekata.
If an allergic reaction to telavancin occurs, discontinue treatment and institute appropriate therapy.
Če se pojavi alergijska reakcija na telavancin, je treba ukiniti zdravilo in začeti z ustreznim zdravljenjem.
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or shortly following treatment.
Zato je treba razmisliti o tej diagnozi pri bolnikih, ki imajo diarejo med
Information to be collected shall include data on renal impairment, fatal outcomes (assessed for causality), cardiac disorders, liver and hepatobiliary disorders, tinnitus and hearing loss, adherence to the SmPC and off label use.
Informacije, ki bodo zbrane, bodo vključevale podatke o ledvičnih okvarah, smrtnih izidih (ocenjenih glede na vzročno zvezo), srčnih boleznih, boleznih jeter, žolčnika in žolčevodov, tinitusu in izgubi sluha, upoštevanju Povzetka glavnih značilnosti zdravila ter nenamenski uporabi zdravila.
Telavancin is a low clearance active substance with a mean (SD) CL of 13.1 (2.0) ml/hr/kg in subjects with normal renal function, corresponding to a total CL of approximately 1 l/hr in a 75 kg subject.
Telavancin je zdravilna učinkovina z nizkim očistkom, s povprečnim (SD) CL 13,1 (2,0) ml/hr/kg pri osebah z normalnim delovanjem jeter, kar ustreza celokupnemu CL v vrednosti približno 1 l za osebo, ki tehta 75 kg.
• The need to counsel patients on important risks associated with Vibativ therapy and appropriate
• Bolnike je treba poučiti o pomembnih tveganjih, ki so povezana z zdravljenjem z zdravilom Vibativ, ter o ustreznih varnostnih ukrepih ob uporabi zdravila.
Discard any unused solution.
Neuporabljeno raztopino odvrzite.
Antibiotic-associated colitis and pseudomembranous colitis
Kolitis, povezan z antibiotiki, in psevdomembranski kolitis
The pregnancy status of women of childbearing potential must be established prior to dosing with telavancin and women of childbearing potential must use effective contraception during
Pred uvedbo zdravljenja s telavancinom je treba preveriti, ali je bolnica v rodni dobi noseča, in bolnice v rodni dobi morajo v času zdravljenja uporabljati učinkovito
If you are given more VIBATIV than you should receive, the chance of experiencing the following side effects increases: disturbed taste, nausea (feeling sick), vomiting, reactions at the site of the infusion, headache, rash, skin flushing of the upper body.
Če ste uporabili večji odmerek zdravila VIBATIV, kot bi smeli Če prejmete več zdravila VIBATIV, kot bi ga smeli prejeti, se poveča verjetnost za pojav naslednjih neželenih učinkov: spremembe okusa, navzeja (občutek slabosti), bruhanje, reakcije na mestu infuzije, glavobol, izpuščaj, sindrom rdečeličneža .
It is not known if telavancin passes into breast milk in humans.
Ni znano, ali se telavancin pri ljudeh izloča v materino mleko.
Powder for concentrate for solution for infusion
prašek za koncentrat za raztopino za infundiranje
No clinically significant differences in pharmacokinetics of telavancin were observed between healthy elderly and healthy young subjects.
Med zdravimi starejšimi in zdravimi mladimi osebami ni bilo opaženih nobenih klinično pomembnih razlik v farmakokinetiki telavancina.